Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
BCRX | US
0.20
2.71%
Healthcare
Biotechnology
30/06/2024
04/10/2024
7.58
7.55
7.63
7.44
BioCryst Pharmaceuticals Inc. a biotechnology company discovers novel oral and small-molecule medicines. The company markets peramivir injection an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB RAPIACTA and PERAMIFLU names; and ORLADEYO an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX9930 an oral factor D inhibitor for complement-mediated diseases; and Galidesivir to treat various RNA viruses including Marburg Yellow Fever Ebola and Zika. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co. Ltd.; Seqirus UK Limited; Shionogi & Co. Ltd.; Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research Ltd. BioCryst Pharmaceuticals Inc. was founded in 1986 and is headquartered in Durham North Carolina.
View LessLow Debt to Equity (< 0.25)
Strong Revenue Growth (> 10%)
Price Below SMA10D
Smallcap (300M - 2B USD)
High Market Beta (> 0.8)
Rich in Valuation (Price to Book > 8)
Weak Operating Margin (< 10%)
Weak Sharpe Ratio (< 0.3)
Bearish: Increased Volatility (6-month > 1-month volatility)
10 days
30.1%1 month
28.5%3 months
46.2%6 months
61.7%-
-
56.59
-1.79
1.80
-12.20
5.56
-0.28
-52.71M
1.57B
1.57B
-
8.01
-
32.50
-1.93K
14.41
11.85
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
Range10D
0.95
Range1M
1.10
Range3M
2.52
Rel. volume
0.60
Price X volume
7.96M
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Recursion Pharmaceuticals Inc. Class A Common Stock | RXRX | Biotechnology | 6.11 | 1.72B | 0.00% | n/a | 15.38% |
Arvinas Inc | ARVN | Biotechnology | 24.96 | 1.71B | 1.05% | n/a | 0.38% |
PROK | PROK | Biotechnology | 1.695 | 1.65B | 3.04% | n/a | -0.69% |
NewAmsterdam Pharma Company N.V. Ordinary Shares | NAMS | Biotechnology | 18.22 | 1.64B | 4.53% | n/a | 0.15% |
Bicycle Therapeutics Limited | BCYC | Biotechnology | 23.6 | 1.63B | 4.61% | n/a | 4.89% |
Ardelyx Inc | ARDX | Biotechnology | 6.82 | 1.61B | -1.59% | n/a | 71.36% |
Syndax Pharmaceuticals Inc | SNDX | Biotechnology | 18.82 | 1.60B | -3.19% | n/a | 0.26% |
Belite Bio Inc | BLTE | Biotechnology | 50.99 | 1.56B | 4.68% | n/a | 0.00% |
Immunocore Holdings plc | IMCR | Biotechnology | 31.11 | 1.56B | 0.06% | n/a | 131.69% |
Ocular Therapeutix Inc | OCUL | Biotechnology | 9.84 | 1.53B | 5.69% | n/a | 19.83% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Fox Factory Holding Corp | FOXF | Recreational Vehicles | 40.42 | 1.68B | 0.17% | 42.66 | 64.69% |
Winnebago Industries Inc | WGO | Recreational Vehicles | 57.84 | 1.66B | 0.98% | 21.48 | 56.33% |
Steelcase Inc | SCS | Building Products & Equipment | 12.97 | 1.47B | 0.78% | 12.50 | 65.47% |
REV Group Inc | REVG | Recreational Vehicles | 27.56 | 1.43B | 0.00% | 6.15 | 63.13% |
Janus International Group Inc. | JBI | Building Products & Equipment | 9.79 | 1.42B | 2.73% | 11.54 | 116.21% |
Pitney Bowes Inc | PBI | Building Products & Equipment | 6.92 | 1.24B | 1.91% | n/a | -571.93% |
ARLO TECHNOLOGIES INC | ARLO | Building Products & Equipment | 11.47 | 1.15B | 0.09% | n/a | 19.46% |
Camping World Holdings Inc | CWH | Recreational Vehicles | 23.44 | 1.06B | -0.38% | n/a | 3644.76% |
Malibu Boats Inc | MBUU | Recreational Vehicles | 39.7 | 793.63M | -0.68% | n/a | 1.50% |
Latham Group Inc. | SWIM | Building Products & Equipment | 6.64 | 767.43M | 0.00% | 61.27 | 77.00% |
Parameter | Company | Industry | Indicator |
---|---|---|---|
Enterprise to EBITDA | -12.20 | 0.76 | Cheaper |
Ent. to Revenue | 5.56 | 3,674.48 | Cheaper |
PE Ratio | - | 38.01 | - |
Price to Book | 56.59 | 14.10 | Expensive |
Dividend Yield | - | 2.22 | - |
Std. Deviation (3M) | 46.22 | 74.67 | Lower Risk |
Debt to Equity | -1.79 | -1.82 | Cheaper |
Debt to Assets | 1.80 | 0.26 | Expensive |
Market Cap | 1.57B | 3.73B | Emerging |